Shares of Bristol-Myers Squibb Company (BMY) are trading -5% lower at a price of $67.33 at the time of this writing. The stock is trailing behind peers on a slightly depressed day for the Health Care sector.


Bristol-Myers Squibb Company has been trading between a 52-week high of $80.03 and a 52-week low of $52.01. The stock has a market cap of $144 Billion.

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

Lupin gets USFDA approval to market generic cancer treatment drug
Business Standard 08-29-22

Bristol Myers-JNJ Partnered Secondary Stroke Drug Misses Endpoint, But Companies See Enough Potential For Phase 3 Trials
Benzinga 08-29-22

Bristol Myers Squibb: Late-Breaking Results From Phase 2 AXIOMATIC-SSP Study of Milvexian, an Investigational Oral Factor XIa Inhibitor, Show Favorable Antithrombotic Profile in Combination With Dual Antiplatelet Therapy
Finanz Nachrichten 08-28-22

Gilead hits back at Bristol Myers'' Supreme Court petition in CAR-T patent feud
FiercePharma 08-26-22

Pfizer – Consensus Indicates Potential 22.8% Upside
DirectorsTalk 08-26-22